InMed recently reported results for the first quarter of FY19 and continues to make solid progress in bringing INM-750 for epidermolysis bullosa (EB) into the clinic by H219. So far, its selected formulation has demonstrated good drug penetration as a topical formulation, a clean safety profile and that each of the two cannabinoid components plays an important and independent role in combating EB, which is an especially important finding from a regulatory point of view for any combination pro
20 Nov 2018
InMed Pharmaceuticals - Biosynthesis and INM-750 Progress on Track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
InMed Pharmaceuticals - Biosynthesis and INM-750 Progress on Track
- Published:
20 Nov 2018 -
Author:
Maxim Jacobs -
Pages:
4
InMed recently reported results for the first quarter of FY19 and continues to make solid progress in bringing INM-750 for epidermolysis bullosa (EB) into the clinic by H219. So far, its selected formulation has demonstrated good drug penetration as a topical formulation, a clean safety profile and that each of the two cannabinoid components plays an important and independent role in combating EB, which is an especially important finding from a regulatory point of view for any combination pro